Cantab Phase II trial fails

Cantab (LSE:CTB, CNTBY) said a Phase II trial of its TH-GW vaccine to treat genital warts failed and that its partner for the program, SmithKline Beecham Biologicals (Rixensart, Belgium), discontinued...